Clinical trial NCT02374424: Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients
Official title: Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Before High-Dose Chemotherapy BEAM With Autologous Stem Cell Transplantation (ASCT)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Diffuse, Large B-Cell, Lymphoma
Lead sponsor: Fondazione Italiana Linfomi - ETS
Sponsor class: OTHER
First posted: 2015-02-27
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Aim of this trial is to assess the efficacy of new anti-CD20 antibody (GA101) in association with DHAP as induction therapy before high dose chemotherapy BEAM with ASCT in patients with relapsed/refractory DLBCL.

Detailed description: This is a prospective, multicenter, single arm, phase II trial in young patients (18-65 years) affected by relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) at diagnosis,eligible to high-dose therapy.

Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.

The study is designed primarily to evaluate the efficacy of GA101-DHAP in patients with DLBCL who have relapsed or are refractory to one chemotherapy regimen and secondarily to assess safety and capability to mobilize peripheral stem cells The study is designed with two stages and with stopping rules after the first stage. In particular, at the end of the first stage, the study will be stopped if the efficacy is too low or if the toxicity, measured during the drug administration period, is too high with respect to pre-defined thresholds. .

Eligibility criteria: Inclusion Criteria:

1. 18≥ Age \< 65
2. Relapsed/refractory disease after receiving one line of standard R-CHOP like chemotherapy
3. Diffuse Large B-cell Lymphoma at relapse. The re-biopsy is particularly recommended if relapse is over 1 year from previous complete remission. If this is harmful for the patient, the patient can be enrolled if archival tumor sample and block from first diagnosis are available.
4. Measurable and/or evaluable disease
5. Any Ann Arbor stage and IPI group at relapse
6. Performance status \< 2 according to Eastern Cooperative Oncology Group (ECOG) scale unless due to lymphoma
7. No Central Nervous System (CNS) disease (meningeal and/or brain involvement by lymphoma)
8. Adequate haematological counts: Absolute Neutrophil Count (ANC) \> 1.5 x 109/L, Hgb \> 10.5 g/dl (transfusion independent), Platelet count \> 75 x 109/L (transfusion independent), with the exception of cytopenia due to lymphoma bone marrow involvement
9. Normal liver function (ALP, AST, ALT, GGT, conjugated bilirubin total \< 2 x ULN) if not related to lymphoma
10. Normal kidney function (creatinine clearance \>= 80 ml/min)
11. Cardiac ejection fraction \> 50% (MUGA scan or echocardiography)
12. Normal lung function
13. Absence of active infections
14. Non peripheral neuropathy or active neurological non neoplastic disease of CNS
15. Non major surgical intervention prior 3 months to randomization if not due to lymphoma and/or not other disease life-threatening that can compromise chemotherapy treatment
16. Disease free of prior malignancies other than lymphoma for \> 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
17. Life expectancy \> 6 months
18. No psychiatric illness that precludes understanding concepts of the trial or signing ten informed consent
19. Written informed consent
20. Women must be:

    1. postmenopausal for at least 1 year (must not have had a natural menses for at least 12 months)
    2. surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
    3. abstinent (at the discretion of the investigator/per local regulations), or
    4. if sexually active, be practicing a highly effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (eg, condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel, male partner sterilization) as local regulations permit, before entry, and must agree to continue to use the same method of contraception throughout the study. They must also be prepared to continue birth control measures for at least 18 months after terminating treatment.
21. Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening
22. Men must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug.

Exclusion Criteria:

1. Diagnosis of Lymphoblastic Lymphoma, Burkitt Lymphoma, Non Hodgkin Lymphoma CD20 negative, Mantle Cell Lymphoma, Follicular Lymphoma, Primary Mediastinal Lymphoma
2. Age ≥ 65 years
3. Patients ineligible to high-dose chemotherapy
4. Performance status \> 2 according to ECOG scale if not due to lymphoma
5. Patients who previously received GA101 (obinutuzumab) are excluded.
6. Patient has known or suspected hypersensitivity or intolerance to Rituximab
7. Patient has received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. Concurrent participation in nontreatment studies is allowed, if it will not interfere with participation in this study.
8. CNS disease (meningeal and/or brain involvement by lymphoma)
9. History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
10. Positive test results for chronic hepatitis B infection (defined as positive HBsAg serology). Patients with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing.
11. Positive test results for hepatitis C (HCV antibody serology testing). Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
12. Known history of HIV seropositive status. For patients with unknown HIV status, HIV testing will be performed at screening if required by local regulations.
13. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug
14. Uncontrolled or severe cardiovascular disease including myocardial infarction within six months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
15. Cardiac ejection fraction \< 45% (MUGA scan or echocardiography)
16. Creatinine clearance \< 45 ml/min
17. Presence of major neurological disorders
18. Active infection
19. Major surgical intervention prior 3 months to randomization if not due to lymphoma and/or other disease life-threatening that can compromise chemotherapy treatment
20. Prior malignancies other than lymphoma in the last 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
21. Life expectancy \< 6 months
22. Any other coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
23. If female, the patient is pregnant or breast-feeding.

Primary outcomes:
measure: Aim of this trial is to assess the efficacy of new anti-CD20 antibody (GA101) in association with DHAP as induction therapy before high dose chemotherapy BEAM with ASCT in patients with relapsed/refractory DLBCL.
timeFrame: 4 months
Secondary outcomes:
measure: Overall Response Rate (ORR) prior to consolidation with BEAM and ASCT
timeFrame: 2 years
measure: Progression free survival (PFS) at 6 month after the end of treatment (EOT)
timeFrame: 6 month
measure: Overall Survival (OS) at 2 years after the EOT
timeFrame: 2 years
measure: Toxicity: Severe, life-threatening, fatal (grade 3, 4 and 5) and/or serious adverse events
timeFrame: 2 years
measure: The hematopoietic cell mobilization
timeFrame: 2 years
measure: Feasibility: the rate of patients actually proceeding to ASCT
timeFrame: 2 years
Other outcomes:
Locations:
city: Vicenza
country: Italy
facility: Ospedale San Bortolo
state: VI
city: Bolzano
country: Italy
facility: Ospedale di Bolzano, Reparto di Ematologia & CTMO
city: Firenze
country: Italy
facility: A.O. Universitaria Careggi
city: Mestre
country: Italy
facility: Ospedale dell'Angelo, U.O. Ematologia
city: Modena
country: Italy
facility: A.O. Universitaria Policlinico Di Modena
city: Pavia
country: Italy
facility: Ematologia Policlinico San Matteo
city: Perugia
country: Italy
facility: AO di Perugia S. Maria della misericordia
city: Roma
country: Italy
facility: Ematologia Ospedale S.Camillo Forlanini
city: Roma
country: Italy
facility: Policlinico Umberto I - Università "La Sapienza"
city: Roma
country: Italy
facility: Ematologia e Trapianto Istituto Regina Elena IFO
Study officials:
affiliation: Dipartimento di Biotecnologie Cellulari ed Ematologia, "La Sapienza" Roma
name: Maurizio Martelli, MD
role: PRINCIPAL_INVESTIGATOR
References: